'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
复制标题
DOI：
10.3390/curroncol30040330
复制
发表时间：
2023-04-20
期刊：
影响因子：
--
通讯作者：
Raphael J
中科院分区：
文献类型：
--
作者：
Verma S;Breadner D;Raphael J
抗体药物偶联物 (ADC) 是一类相对较新的药物，有望改善特定癌症的治疗效果。通过将细胞毒剂递送至表达特定抗原的肿瘤细胞，ADC 可实现更好的治疗指数和更强的效力。 ADC 已被批准用于治疗多种血液学和实体恶性肿瘤，包括乳腺癌、尿路上皮癌和胃癌。最近，曲妥珠单抗 deruxtecan (TDXd) 是第一个被批准用于既往治疗的转移性 HER2 突变非小细胞肺癌 (NSCLC) 的 ADC。许多有前景的 ADC 正在筹备用于非小细胞肺癌的临床开发，包括 sacituzumab govitecan、patritumab deruxtecan、datopotamab deruxtecan 和 tusamitamab ravtansine。人们希望这些药物能够满足特定患者群体未满足的需求，包括目前具有不可靶向突变的患者。我们希望这些药物，例如 TROP2 靶向 ADC，也将为 NSCLC 的治疗提供更多选择，以改善患者的预后。在这篇全面综述中，我们将讨论最新的证据，包括 NSCLC 中新型 ADC 候选药物的靶标、疗效和安全性。随着这些新的 ADC 和组合找到进入临床实践的途径，我们还将简要讨论具体的毒性、新型生物标志物、克服耐药机制、挑战和前进的道路。
Antibody-Drug conjugates (ADCs) are a relatively new class of drugs with a promise to improve the outcomes in specific cancers. By delivering the cytotoxic agent to tumor cells expressing specific antigens, ADCs achieve a better therapeutic index and more potency. ADCs have been approved for several hematological and solid malignancies, including breast, urothelial and gastric carcinoma. Recently, trastuzumab deruxtecan (TDXd) was the first ADC approved for previously treated metastatic HER2-mutant non-small cell lung cancer (NSCLC). Many promising ADCs are in the pipeline for clinical development in non-small cell lung cancer, including sacituzumab govitecan, patritumab deruxtecan, datopotamab deruxtecan and tusamitamab ravtansine. There is a hope that these drugs would cater to the unmet need of specific patient populations, including patients with currently untargetable mutations. We hope these drugs, e.g., TROP2 targeted ADCs, will also give more options for therapy in NSCLC to improve outcomes for patients. In this comprehensive review, we will be discussing the recent evidence including targets, efficacy and the safety of newer ADC candidates in NSCLC. We will also briefly discuss the specific toxicities, novel biomarkers, overcoming resistance mechanisms, challenges and the way forward, as these new ADCs and combinations find a way into the clinical practice.
登录
查看更多内容
影响因子：
16.2
作者：
Chen, Yu-Fei;Xu, Ying-ying;Shao, Zhi-Ming;Yu, Ke-Da
通讯作者：
Yu, Ke-Da
影响因子：
4.5
作者：
Betts, Alison M.;Haddish-Berhane, Nahor;Johnson, Theodore R.
通讯作者：
Johnson, Theodore R.
影响因子：
82.9
作者：
Boshuizen, Julia;Koopman, Louise A.;Parren, Paul W. H. I.
通讯作者：
Parren, Paul W. H. I.
影响因子：
28.5
作者：
Criscitiello C;Morganti S;Curigliano G
通讯作者：
Curigliano G
概率疗法：一种新兴类型的疗法，旨在增强靶向效应，并降低肿瘤毒性，用于免疫肿瘤学。
DOI：
10.1158/1078-0432.ccr-19-1457
发表时间：
2020-03-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Autio KA;Boni V;Humphrey RW;Naing A
通讯作者：
Naing A